US banks continue moving towards deal making in the cannabis sector, with Bank of America (NYSE:BAC) now holding just over US$2 million worth of stock in a large Canadian marijuana firm.

The bank reported that it held 382,352 shares of Aphria (NYSE:APHA,TSX:APHA) as of its latest disclosure with the US Securities and Exchange Commission, as per a Finance Daily report on Saturday (May 4).


Bank of America has taken decisive steps forward in the marijuana industry as it recently launched its coverage of the space.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

In April, the banking firm issued its first analyst report on the Canadian cannabis space.

While the bank shows its willingness to hop on board the legal cannabis industry, the report raises some questions on the future state of the Canadian market.

“There are over 50 publicly traded Canadian cannabis licensed producers, far too many for a cannabis market the size of Canada’s, in our view,” analyst Chris Carey indicated in the report.

This move represents another sign of the US bank expanding its presence in the cannabis sector.

Bank of America’s subsidiary BofA Merrill Lynch is acting as an underwriter for CannTrust Holdings (NYSE:CTST,TSX:TRST). Last Thursday (May 2), the Canadian cannabis firm priced an offering at US$5.50 per share, seeking to gain gross proceeds of approximately US$170 million.

CannTrust closed the offering on Monday and reported the sale of 30.9 million shares for its estimated gross return.

Aphria is trying to turn the page on its previous reputation. After a turbulent period of time in its operations, including facing short sellers and takeover bids, the company’s new management team is seeking to move past those times and present a new face to investors.

In an interview with BNN Bloomberg, Irwin Simon, chairman and interim CEO of the company, admitted there has been a “black cloud” surrounding the company and its stock.

“I’m amazed at what this company’s been able to deal with, and our big challenge has been to show what’s here to get people really to believe in what we’re able to do,” the executive said as he listed some of the recent complications for Aphria.

Simon explained that the company is in no rush to proceed with a deal to guarantee an entry into the US market through an agreement with a multi-state operator (MSO).

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Interest for agreements between Canadian firms and US operators have seen increasing attention from investors thanks to the Canopy Growth (NYSE:CGC,TSX:WEED) deal with MSO Acreage Holdings (CSE:ACGR.U,OTCQX:ACRGF).

The unique structure of the arrangement between Canopy and Acreage has gained popularity with experts in the space, who are projecting more partnerships like this one.

Matt Bottomley, equity analyst covering the marijuana space with Canaccord Genuity (TSX:CF,OTC Pink:CCORF), told shareholders during the Arcview Investor Forum in Vancouver that if this deal structure catches on in the market he expects to see “almost every large-cap LP enter the US space.”

Shares of Aphria dipped on Monday’s (May 6) trading session by 0.72 percent in New York. The company finished the day at a price of US$6.89.

Aphria dropped in Toronto as well, reaching C$9.26, which represents a marginal decline in value of 0.64 percent.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: Acreage Holdings is a client of the Investing News Network. This article is not paid-for content.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Seth Rogen’s New Cannabis Brand are Now Available at Apothecarium Dispensaries in San Francisco , Berkeley and Capitola

The Apothecarium is offering cannabis from Houseplant, the cannabis lifestyle brand founded by Seth Rogen and Evan Goldberg at its five California dispensaries. The Apothecarium has three San Francisco locations (Castro, SOMA and Marina ) and one each in Berkeley and Capitola (outside of Santa Cruz ).

Keep reading... Show less

Love Hemp Group PLC (AQSE:LIFE)(OTCQB:WRHLF), one of the UK’s leading CBD and hemp product suppliers, announces that Charles Lamb will be stepping down as a Non-Executive Independent Director of the Company, with effect from April 16, 2021, to focus on his other business interests

Charles has been an integral part of the Board’s efforts to grow the Company since its inception and has played a key role in the Company’s shift in strategy to focus on growing the Love Hemp brand globally.

Keep reading... Show less

Expects to file its 2020 Annual Financial Statements on or before May 31, 2021

Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”) today announced that, as a result of the COVID-19 Pandemic measures, it will not be in a position to file its audited annual financial statements, the related management’s discussion and analysis and related CEO and CFO certificates (the “Annual Filings”) before the required deadline of April 30, 2021 (the “Specified Requirements”).

Keep reading... Show less

Recreational cannabis remains illegal in all Australia’s states and territories with the exception of the Australian Capital Territory (ACT). But could that change in the future?

So far there are no clear indicators as to when or if Australia could legalise recreational cannabis, but attitudes seem to be changing. Public support is growing, and there’s even some political acceptance.

Read on to learn more about when Australia may legalise recreational cannabis.

Keep reading... Show less